致《泌乳素瘤停用卡麦角林后高生化复发率：是否有必要重新开始治疗？》的信 - Suppr | 超能文献

Letter to "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?".

作者信息

Candemir Burcu, Akın Şafak

机构信息

University of Health Sciences, Gulhane Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey.

出版信息

Endocrine. 2021 Jan;71(1):262. doi: 10.1007/s12020-020-02574-0. Epub 2021 Jan 4.

DOI:10.1007/s12020-020-02574-0

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Letter to "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?".致《泌乳素瘤停用卡麦角林后高生化复发率：是否有必要重新开始治疗？》的信

Endocrine. 2021 Jan;71(1):262. doi: 10.1007/s12020-020-02574-0. Epub 2021 Jan 4.

2

Response to Letter to the Editor: "High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?".

Endocrine. 2021 Jan;71(1):263-264. doi: 10.1007/s12020-020-02584-y. Epub 2021 Jan 21.

3

Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.卡麦角林，一种治疗催乳素瘤和非肿瘤性高催乳素血症的有前景的药物。

Intern Med. 2001 Sep;40(9):845-6. doi: 10.2169/internalmedicine.40.845.

4

High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?催乳素瘤停用卡麦角林后生化复发率高：是否有必要重新开始治疗？

Endocrine. 2020 Oct;70(1):143-149. doi: 10.1007/s12020-020-02388-0. Epub 2020 Jun 17.

5

Pituitary gland: can prolactinomas be cured medically?垂体：催乳素瘤可以通过药物治愈吗？

Nat Rev Endocrinol. 2010 Apr;6(4):186-8. doi: 10.1038/nrendo.2009.278.

6

Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.卡麦角林治疗的泌乳素瘤患者当前的药物撤药策略：一项系统评价和荟萃分析。

Pituitary. 2015 Oct;18(5):745-51. doi: 10.1007/s11102-014-0617-2.

7

Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.多巴胺激动剂停药后高催乳素血症的复发及泌乳素瘤复发的可能预测因素

J Endocrinol Invest. 2016 Dec;39(12):1377-1382. doi: 10.1007/s40618-016-0483-z. Epub 2016 May 31.

8

Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.停止使用长效卡麦角林治疗肿瘤性和非肿瘤性高催乳素血症。

N Engl J Med. 2003 Nov 20;349(21):2023-33. doi: 10.1056/NEJMoa022657.

9

Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.长期使用卡麦角林治疗停药后高催乳素血症复发。

J Clin Endocrinol Metab. 2009 Jul;94(7):2428-36. doi: 10.1210/jc.2008-2103. Epub 2009 Mar 31.

10

Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.建立泌乳素瘤对卡麦角林反应的临床预测规则。

J Clin Endocrinol Metab. 1999 Dec;84(12):4746-7. doi: 10.1210/jc.84.12.4746-a.

本文引用的文献

1

High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?催乳素瘤停用卡麦角林后生化复发率高：是否有必要重新开始治疗？

Endocrine. 2020 Oct;70(1):143-149. doi: 10.1007/s12020-020-02388-0. Epub 2020 Jun 17.

2

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.高泌乳素血症的诊断和治疗：内分泌学会临床实践指南。

J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.